Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Targeting Attenuated Interferon-α to Myeloma Cells with a CD38 Antibody Induces Potent Tumor Regression with Reduced Off-Target Activity.

Pogue SL, Taura T, Bi M, Yun Y, Sho A, Mikesell G, Behrens C, Sokolovsky M, Hallak H, Rosenstock M, Sanchez E, Chen H, Berenson J, Doyle A, Nock S, Wilson DS.

PLoS One. 2016 Sep 9;11(9):e0162472. doi: 10.1371/journal.pone.0162472. eCollection 2016.

2.

Enhancement and suppression of signaling by the conserved tail of IgG memory-type B cell antigen receptors.

Horikawa K, Martin SW, Pogue SL, Silver K, Peng K, Takatsu K, Goodnow CC.

J Exp Med. 2007 Apr 16;204(4):759-69. Epub 2007 Apr 9.

3.

The receptor for type I IFNs is highly expressed on peripheral blood B cells and monocytes and mediates a distinct profile of differentiation and activation of these cells.

Pogue SL, Preston BT, Stalder J, Bebbington CR, Cardarelli PM.

J Interferon Cytokine Res. 2004 Feb;24(2):131-9.

PMID:
14980077
4.

B cell antigen receptor-induced activation of Akt promotes B cell survival and is dependent on Syk kinase.

Pogue SL, Kurosaki T, Bolen J, Herbst R.

J Immunol. 2000 Aug 1;165(3):1300-6.

6.

Self-tolerance checkpoints in B lymphocyte development.

Goodnow CC, Cyster JG, Hartley SB, Bell SE, Cooke MP, Healy JI, Akkaraju S, Rathmell JC, Pogue SL, Shokat KP.

Adv Immunol. 1995;59:279-368. Review. No abstract available.

PMID:
7484462
7.
9.

Generation and characterization of continuous lines of CD8+ suppressor T lymphocytes.

Aune TM, Pogue SL.

J Immunol. 1989 Jun 1;142(11):3731-9.

PMID:
2469724

Supplemental Content

Loading ...
Support Center